Gastroenterologie
a hepatologie

Standard diagnostic and therapeutic procedure for chronic infection of hepatitis C virus

Petr Urbánek ^{Orcid.org  1}, Jan Šperl ^{Orcid.org  2}, Stanislav Plíšek ^{Orcid.org  3}, Luděk Rožnovský⁴, Petr Kümpel ^{Orcid.org  5}, Petr Husa⁶

+ Affiliation
¹ Interní klinika 1. LF UK a ÚVN – VFN Praha
² Klinika hepatogastroenterologie, Transplantcentrum, IKEM, Praha
³ Klinika infekčních nemocí LF UK a FN Hradec Králové
⁴ Klinika infekčního lékařství LF OU a FN Ostrava
⁵ Infekční oddělení, Slezská nemocnice v Opavě, p.o.
⁶ Klinika infekčních chorob LF MU a FN Brno

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. European Association for Study of Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60 (2): 392–420. doi: 10.1016/j.jhep.2013.11.003.
2. Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13): 1207–1217. doi: 10.1056/NEJMoa1009482.
3. Jacobson IM, McHutchison JG, Dusheiko G  et al. Telaprevir for previously untreat­- ed chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25): 2405–2416. doi: 10.1056/NEJMoa1012912.
4. Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13): 1195–1206. doi: 10.1056/NEJMoa1010494.
5. Zeuzem S, Andreone P, Pol S et al. Tela­previr for retreatment of HCV infection. N Engl J Med 2011; 364 (25): 2417–2428. doi: 10.1056/NEJMoa1013086.
6. Castéra L, Sebastiani G, Le Bail B et al. Prospective comparison of two algo­rithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52 (2): 191–198. doi: 10.1016/j.jhep.2009.11.008.
7. Castéra L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128 (2): 343–350.
8. Lawitz E, Mangia A, Wyles D et al.  Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368 (20): 1878–1887. doi: 10.1056/ /NEJMoa1214853.
9. Jacobson I, Dore GJ, Foster GR et al.  Simeprevir (TMC435) with peginterferon/ /ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a phase III trial. J Hepatol 2013; 58 (Suppl 1): S574.
10. Manns M, Marcellin P, Poordad F et al. Simeprevir (TMC435) with peginterferon/ /ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive ­patients: results from QUEST-2, a Phase III trial. J Hepatol 2013; 58 (Suppl 1): S568.
11. Poordad F, Manns MP, Marcellin P et al. Simeprevir (TMC435) with peginterferon/ /ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive pa­tients: results from QUEST-2, a phase III trial. Gastroenterology 2013; 144: S151.
12. Lawitz E, Forns X, Zeuzem S et al.  Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferonbased therapy:  results from PROMISE, a phase III trial. Gastroenterology 2013; 144: S151.
13. Hezode C, Hirschfield GM, Ghesquiere W et al. Daclatasvir, an NS5A replication ­complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment- -naive HCV-genotype 1 or 4 subjects: phase 2b COMMAND-1 SVR12 results.  Hepatology 2012; 56 (Suppl 1): 553A–554A.
14. Gane EJ, Stedman CA, Hyland RH et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368 (1): 34–44. doi: 10.1056/NEJMoa1208953.
15. Lalezari JP, Nelson DR, Hyland RH et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naive pa- tients with HCV infection: the QUANTUM study. J Hepatol 2013; 58 (Suppl 1): S346.
16. Sulkowski MS, Rodriguez-Torres M, ­Lalezari JP et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in pa­tients co-infected with HIV (PHOTON-1).  Hepatology 2013; 58 (Suppl 1): 313A–314A.
17. Jacobson I, Ghalib RH, Rodriguez-­ -Torres M et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responders patients: the COSMOS study. Hepatology 2013; 58 (Suppl 1): 1379A.
18. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370 (3): 211–221. doi: 10.1056/NEJMoa1306218.
19. Fontana RJ, Hughes EA, Bifano M et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13 (6): 1601–1605. doi: 10.1111/ajt.12209.
20. Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368 (20):  1867–1877. doi: 10.1056/NEJMoa1214854.
21. Zeuzem S, Dusheiko G, Salupere R et al. Sofosbuvir plus ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology 2013; 58 (Suppl 1): 733A.
22. Lawitz E, Poordad F, Brainard DM et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3  treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Hepatology 2013; 58 (Suppl 1): 1380A.
23. Lawitz E, Lalezari JP, Hassanein T et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cir­rhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13 (5): 401–408. doi: 10.1016/S1473-3099 (13) 70033-1.
24. Strader DB, Wright T, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39 (4): 1147–1171.
25. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47 (RR-19): 1–39.